Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CD74 | P04233 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218118 | 0.87 | KMT2A (0.57) | KMT2AADORA3ADORA2AADORA1HTT | |
| Ammonia Solution, Strong SCHEMBL10418488 | 0.85 | KMT2A (0.55) | KMT2AADORA3ADORA2AADORA1HTT | |
| SCHEMBL27832176 | 0.82 | MIF (0.63) | METMIFALDH1A1 | |
| SCHEMBL15060395 | 0.82 | NPC1 (0.50) | KMT2AHTTMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28001364 | 0.82 | KMT2A (0.48) | KMT2AHTTMEN1ALDH1A1LMNA | |
| SCHEMBL29007611 | 0.82 | HTT (0.65) | KMT2AHTTMEN1CYP2C9ALDH1A1 | |
| SCHEMBL27551728 | 0.82 | KMT2A (0.50) | KMT2AADORA3ADORA2AADORA1HTT | |
| SCHEMBL182038 | 0.82 | RPA1 (0.45) | HSD17B1HSD17B2MIFCD74ALDH1A1 | |
| SCHEMBL182519 | 0.81 | SMN1; SMN2 (0.49) | KMT2AHTTMEN1CYP2C9ALDH1A1 | |
| SCHEMBL15072164 | 0.80 | KMT2A (0.50) | KMT2AHTTMEN1CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926708-B1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2014-06-18 | — | — | EP | disclosed |
| US-8598359-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2013-12-03 | — | — | US | disclosed |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF (IS) | 2009-06-25 | — | — | US | disclosed |
| CN-101312948-A | Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation | DECODE GENETICS EHF (IS) | 2008-11-26 | — | — | CN | disclosed |
| US-7402684-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENECTICS EHF. (IS) | 2008-07-22 | — | — | US | disclosed |
| EP-1926708-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Chemistry, Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007040681-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040682-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | KMT2A 3243/4885ADORA3 686/4885ADORA2A 630/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | KMT2A 3243/4885ADORA3 686/4885ADORA2A 630/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | KMT2A 3243/4885ADORA3 686/4885ADORA2A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.